Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has raised $76 million in Series A.
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
(Reuters) - Gilead Sciences Inc said on Monday the U.S. Food and Drug Administration had lifted the partial clinical hold placed on its trials testing.
(Reuters) - Gilead Sciences Inc said on Monday the U.S. Food and Drug Administration had lifted the partial clinical hold placed on its trials testing.